Since 1999, the implications of LOX-1 in diseases that involve the activation of the endothelium and that stimulate the expression of factors and molecules that induce inflammation have been identified, where risk factors such as obesity, diabetes mellitus, hypertension, hypercholesterolemia, and smoking are involved. Here, OLR1 is linked to obesity disorder.